European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- -

The "Tablets -0478-" monograph covers tablets intended for oral administration, including immediate-release, modified-release, and prolonged-release formulations. The monograph applies to tablets containing one or more APIs, with or without excipients.

To ensure patients receive the intended dose, the break-mark's efficacy must be assessed during product development. The test: break 30 tablets by hand, weigh one part from each, and check mass uniformity. Not more than one part can fall outside 85-115% of the average mass.

This requirement is so critical that its practical application has been the subject of a European study. The study, conducted by 27 state control laboratories from 22 European countries, found that , underscoring the practical challenges in this area. The uniformity of halved tablets depends heavily on the formulation, geometry, and manufacturing process, embodying the Quality by Design principle where "scorability needs to be built into the tablet". European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

Although friability is sometimes considered a "secondary" test, Monograph 0478 references it explicitly for uncoated tablets.

To comply with Ph. Eur. 0478, tablets must pass a rigorous battery of tests. These tests ensure that the physical characteristics of the tablet translate into reliable therapeutic performance. 1. Uniformity of Dosage Units The "Tablets -0478-" monograph covers tablets intended for

A "monograph" in this context is a collection of quality standards for a specific type of product. Monograph 0478 is a "general" monograph, meaning its requirements apply to all tablets that fall under its definition, regardless of their specific active ingredient. These requirements are legally binding within the European Union, mandated by EU Directives 2001/82/EC and 2001/83/EC, which state that marketing authorization applications must comply with Ph. Eur. texts. Consequently, the standards set forth in monograph 0478 are legally enforceable for any tablet product marketed within the EU, a fact that underscores its critical importance for pharmaceutical manufacturers.

Monograph 0478 defines tablets as solid preparations containing a single dose of one or more active substances. They are primarily produced by compressing particles but can also be made through extrusion or freeze-drying (oral lyophilisates). This general monograph covers various categories, including: . Gastro-resistant and Modified-release Tablets . Effervescent, Soluble, and Dispersible Tablets . The test: break 30 tablets by hand, weigh

: Uncoated tablets containing acid substances and carbonates/hydrogen carbonates. They react rapidly in water to release carbon dioxide, dissolving or dispersing the drug for consumption.

| Test Category | Key Tests and Requirements | | :--- | :--- | | | A test to confirm the identity of the active substance(s) in the tablet, usually by a technique like chromatography or spectroscopy. | | Dissolution/Disintegration | For rapidly dissolving products, a disintegration test may suffice; otherwise, a dissolution test is required. Unless otherwise justified, a suitable dissolution test, such as one described in Ph. Eur. general chapter 2.9.3 , must be carried out. | | Uniformity of Dosage Units | This ensures the dosage form contains the correct amount of drug substance. The harmonised chapter 2.9.40 is the binding requirement for intact tablets, while monograph 0478 provides additional rules for scored tablets. | | Friability | This test (Chapter 2.9.7 ) measures the tendency of tablets to chip or break during handling and transport. | | Resistance to Crushing | This test (Chapter 2.9.8 ) measures the mechanical strength of tablets, ensuring they are hard enough to withstand processing but not too hard to prevent disintegration. | | Microbiological Quality | Tablets must comply with the limits for total microbial count and the absence of specified pathogens as per Chapter 5.1.4 . |